Shell Companies
Compare Stocks
2 / 10Stock Comparison
DMAA vs BRTX
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
DMAA vs BRTX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Shell Companies | Biotechnology |
| Market Cap | $111M | $2M |
| Revenue (TTM) | $0.00 | $383K |
| Net Income (TTM) | $6M | $-13M |
| Gross Margin | — | 79.6% |
| Operating Margin | — | -37.9% |
| Total Debt | $662.00 | $0.00 |
| Cash & Equiv. | $1K | $548K |
DMAA vs BRTX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Feb 25 | May 26 | Return |
|---|---|---|---|
| Drugs Made In Ameri… (DMAA) | 100 | 106.3 | +6.3% |
| BioRestorative Ther… (BRTX) | 100 | 13.5 | -86.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DMAA vs BRTX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
DMAA carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- 6.4% 10Y total return vs BRTX's -100.0%
- Lower volatility, beta 0.00, current ratio 6.27x
- Beta 0.00, current ratio 6.27x
In this particular matchup, BRTX is outpaced on most metrics by others in the set.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +5.0% vs BRTX's -88.7% | |
| Efficiency (ROA) | 2.4% ROA vs BRTX's -224.5% |
DMAA vs BRTX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
DMAA vs BRTX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
BRTX and DMAA operate at a comparable scale, with $383,400 and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $0 | $383,400 |
| EBITDAEarnings before interest/tax | -$726,546 | -$14M |
| Net IncomeAfter-tax profit | $6M | -$13M |
| Free Cash FlowCash after capex | -$414,132 | -$11M |
| Gross MarginGross profit ÷ Revenue | — | +79.6% |
| Operating MarginEBIT ÷ Revenue | — | -37.9% |
| Net MarginNet income ÷ Revenue | — | -33.0% |
| FCF MarginFCF ÷ Revenue | — | -28.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -94.9% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -153.8% |
Valuation Metrics
DMAA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $111M | $2M |
| Enterprise ValueMkt cap + debt − cash | $111M | $1M |
| Trailing P/EPrice ÷ TTM EPS | -189.29x | -0.18x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 9999.00x | — |
| Price / SalesMarket cap ÷ Revenue | — | 4.09x |
| Price / BookPrice ÷ Book value/share | — | 0.19x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
Evenly matched — DMAA and BRTX each lead in 2 of 4 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), DMAA scores 3/9 vs BRTX's 2/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | — | -5.7% |
| ROA (TTM)Return on assets | +2.4% | -2.2% |
| ROICReturn on invested capital | — | -100.4% |
| ROCEReturn on capital employed | — | -124.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | $661 | -$547,890 |
| Cash & Equiv.Liquid assets | $1,351 | $547,890 |
| Total DebtShort + long-term debt | $662 | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (Dividends Reinvested)
DMAA leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DMAA five years ago would be worth $10,643 today (with dividends reinvested), compared to $59 for BRTX. Over the past 12 months, DMAA leads with a +5.0% total return vs BRTX's -88.7%. The 3-year compound annual growth rate (CAGR) favors DMAA at 2.1% vs BRTX's -65.9% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +2.1% | -83.1% |
| 1-Year ReturnPast 12 months | +5.0% | -88.7% |
| 3-Year ReturnCumulative with dividends | +6.4% | -96.0% |
| 5-Year ReturnCumulative with dividends | +6.4% | -99.4% |
| 10-Year ReturnCumulative with dividends | +6.4% | -100.0% |
| CAGR (3Y)Annualised 3-year return | +2.1% | -65.9% |
Risk & Volatility
DMAA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DMAA is the less volatile stock with a 0.00 beta — it tends to amplify market swings less than BRTX's 2.11 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DMAA currently trades 100.0% from its 52-week high vs BRTX's 10.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.00x | 2.11x |
| 52-Week HighHighest price in past year | $10.60 | $2.05 |
| 52-Week LowLowest price in past year | $10.09 | $0.19 |
| % of 52W HighCurrent price vs 52-week peak | +100.0% | +10.0% |
| RSI (14)Momentum oscillator 0–100 | 71.1 | 41.9 |
| Avg Volume (50D)Average daily shares traded | 166K | 5.4M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
DMAA leads in 3 of 6 categories — strongest in Valuation Metrics and Total Returns. 1 category is tied.
DMAA vs BRTX: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — DMAA or BRTX?
Over the past 5 years, Drugs Made In America Acquisition Corp.
Ordinary Shares (DMAA) delivered a total return of +6. 4%, compared to -99. 4% for BioRestorative Therapies, Inc. (BRTX). Over 10 years, the gap is even starker: DMAA returned +6. 4% versus BRTX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — DMAA or BRTX?
By beta (market sensitivity over 5 years), Drugs Made In America Acquisition Corp.
Ordinary Shares (DMAA) is the lower-risk stock at 0. 00β versus BioRestorative Therapies, Inc. 's 2. 11β — meaning BRTX is approximately Infinity% more volatile than DMAA relative to the S&P 500.
03Which has better profit margins — DMAA or BRTX?
Drugs Made In America Acquisition Corp.
Ordinary Shares (DMAA) is the more profitable company, earning 0. 0% net margin versus -22. 4% for BioRestorative Therapies, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DMAA leads at 0. 0% versus -28. 8% for BRTX. At the gross margin level — before operating expenses — BRTX leads at 93. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — DMAA or BRTX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
05Is DMAA or BRTX better for a retirement portfolio?
For long-horizon retirement investors, Drugs Made In America Acquisition Corp.
Ordinary Shares (DMAA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 00)). BioRestorative Therapies, Inc. (BRTX) carries a higher beta of 2. 11 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DMAA: +6. 4%, BRTX: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between DMAA and BRTX?
These companies operate in different sectors (DMAA (Financial Services) and BRTX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: DMAA is a small-cap quality compounder stock; BRTX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.
Compare BRTX vs MESO
MESO is one of the most direct listed alternatives to BRTX.
Compare DMAA vs HCAI
HCAI overlaps with DMAA in an adjacent operating segment worth comparing.
Expand With MESO + XTNT
MESO and XTNT are the strongest missing peers across the current compare set.